Source
Recombinant gene engineering production, E. coli expression.
Product introduction
Semaglutide is a new generation glucagon-like peptide-1 (GLP-1) receptor agonist that reduces glucagon-like peptide-1 secretion by stimulating insulin secretion. Compared to liraglutide, it has a longer fatty chain, increased hydrophobicity, and is closely bound to albumin, covering the DPP-4 enzyme hydrolysis site. It also reduces renal excretion and can extend the half-life to achieve a long-term effect, with a half-life of up to one week. It has very good effects on reducing blood sugar and weight loss.
Product characteristics
- Product origin: E. coli
- Product appearance: white or off-white powder
- Product purity: ≥98%
- Specific activity: 0.7-1.3U/mg
- Quality standard: company standard (different quality standard products can be customized according to different customer needs)
- Storage conditions: store and transport at or below -15°C
- Expiration date: tentatively 18 months
Comparison of this product with the original peptide
Product features
- Complies with regulatory requirements: We can produce high-purity and high-quality standard raw materials that meet GMP requirements. They can be used for scientific research and also exported as raw materials for formulation. For more information, please consult us.
- Complete quality documents: There is a complete quality assurance system and quality documents, and DMF can be applied for.
- No animal origin: produced by recombination, free of exogenous viral contamination, and no animal-derived materials are used in the production process.
- Quality stability: mass production can ensure stable and continuous batch production; small batch-to-batch differences and stable quality.
Related products（For more detailed information, please contact us）
Liraglutide, Tirzepatide